Dr. Aaron discusses benefits of FLEXISEQ.
Green Park Medical Appoints Datuk Dr Sheikh Muszaphar Shukor as Brand Ambassador and Pharma Field Synergy as New Distributor for FLEXISEQ
Kuala Lumpur, 10 June 2014 – In expanding the reach and accessibility of FLEXISEQ to all osteoarthritis (OA) patients across the country, Green Park Medical Ltd (Green Park Medical), the Company that introduced FLEXISEQ in Malaysia as well as the rest of Southeast Asia, has proudly announced today the appointment of Datuk Dr Sheikh Muszaphar Shukor as Brand Ambassador of FLEXISEQ in Malaysia. This announcement follows the appointment of Pharma Field Synergy Sdn Bhd (PFS) by Green Park Medical as the new distributor of FLEXISEQ, a non-invasive treatment gel that manages and alleviates joint pain caused by OA, effective 1 May 2014.
Expanding on the partnership and new business direction for FLEXISEQ in Malaysia, Mr Ooi Eng Jin, Managing Director of PFS said, “Our mission at PFS has always been to increase the accessibility of innovative and effective medicines to the public through collaborations with leaders in their respective therapeutic fields. As PFS now represents FLEXISEQ in Malaysia, we have embarked on a new development plan to ensure that all OA patients across the country are aware of, and can benefit from the important therapeutic role FLEXISEQ can play in their lives.”
NEW STRAITS TIMES : LIFE & TIMES HEALTH FEBRUARY 18, 2014
It has been launched in various countries including Malaysia. Pro Bono Bio recently announced the UK launch of FLEXISEQ, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis.
Chief Operating Officer Michael Earl says: “The proven physical mode of action and the lack of an active pharmaceutical ingredient give FLEXISEQ the best of both worlds: It works and it’s safe. The lack of systemic side effects that have been recorded when drugs are used chronically, such as gastrointestinal bleeding, kidney failure, heart attack and stroke, together with a lack of drug interactions makes it a particularly suitable option for many OA patients, who are elderly and may be suffering from other conditions and taking other medications, which complicate the choice of therapy for their painful joints.”
28th January 2014, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK national launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis1 (OA) following the successful conclusion of the pioneering 2 month Charity partnership phase for the benefit of Arthritis Research UK. The contribution in products that are sold through the Arthritis Research UK website and through LloydsPharmacy has raised over £400,000 for the medical research charity. Sufferers have enthusiastically welcomed the new, effective and safe product that they can self-medicate and it is now going on sale through all leading pharmacies in the
UK. FLEXISEQ comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions and so is safer than the existing drug treatments.
If you are among the estimated 10 to 20% of the adult population who suffer from osteoarthritis of the knee or other joints, then most probably you have tried the supplements glucosamine and chondroitin.
Both glucosamine and chondroitin are natural substances found in cartilage.
Glucosamine is an amino sugar that may help renew cartilage while chondroitin sulfate is a complex carbohydrate that is thought to help cartilage retain water.
Because osteoarthritis causes pain, swelling and stiffness in joints and damages cartilage over time, it is perhaps thought that extra glucosamine and chondroitin could help maintain and perhaps repair the damage caused by this wear and tear of the joints.
People affected by osteoarthritis have a condition where the cartilage (connective tissue) between their bones has gradually wasted away, leading to painful rubbing of bone on bone in the joints.
Without the cartilage, joints are unable to absorb shock and impact, thus affecting movement. Up to 40% of adults above the age of 65 years have symptoms of osteoarthritis.
For millions of sufferers of chronic pain, the dependence on painkillers for relief presets a risk. High doses of painkillers have been found to increase the risk of heart attack, stroke and heart failure, and cause complications such as bleeding ulcers, according to the largest study of its kind by Oxford University, which was recently published in the renowned medical journal The Lancet.
The drugs, which are known as non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used by people with arthritis and other forms of chronic pain.
The study analysed the results of 754 clinical trials of NSAIDs, including diclofenac, ibuprofen, naproxen and the COX-II inhibitors - celecoxib, rofecoxib and lumiracoxib.
It confirmed that these drugs significantly increased the risks of cardiovascular side effects, including death and gastrointestinal problems including internal bleeding.
New clinical trial data published recently in The Journal of Rheumatology, showed that Flexiseq gel was very effective in managing the pain associated with osteoarthritis (OA) and was again found to have a much stronger safety profile than other treatments.
This is the latest high profile publication after winning the German Pharmacy Industry award for innovation in January this year.
Dr Matthias Rother, the publication’s lead author, says ‘This is an important study that confirms the safety and efficacy of Flexiseq for treatment of the chronic pain and stiffness that trouble many patients with OA.
“The effect size seen is comparable to a comparative study using the same design which demonstrated that Flexiseq has equivalent efficacy to the widely used oral NSAID, celecoxib.”
The findings offer hope to OA patients, particularly those at risk from the common gastrointestinal and cardiovascular side effects associated with NSAIDs, such as celecoxib and diclofenac (which has been the subject of further health warnings from the EMA in July).
Professor Conaghan, co-author of the paper, says that OA is a widespread and chronic disease that causes pain and loss of function, which adversely affects patients’ lives.
3rd December 2013, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK Charity launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis₁ (OA). FLEXISEQ’s proven efficacy comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions, and with over 6 million doses administered since launch there have been no reported systemic side effects.
FLEXISEQ is already successfully sold in the early pilot markets of Austria, Germany, Ireland, Malaysia and Singapore. Earlier this year, FLEXISEQ won the Innovation Award 2013 from the Federal Association of German Pharmacists. In June, FLEXISEQ launched in Ireland and became the fastest growing over-the-counter product that pharmacies there had seen in recent times.
It was a weird invite for me to get, a medical device press luncheon. I did email the pr company back who invited me explaining that this was not in my realm of writing but I would love to accept the invite if that offer still stood. Frankly I think they made a mistake and was hoping I'd decline; but considering my autoimmune disease there was no way I was missing the opportunity!
Flexiseq is a new topical gel targeting pain in osteoarthritis sufferers. You may know that since suffering through chikungunya in 2008 I am now laden with a reactive arthritis in my hips, wrists and ankles. I take a lot of pills twice daily.
October 2013 – FLEXISEQ, the award winning new drug-free treatment for Osteoarthritis is now available in Singapore. Clinically proven* in Europe to be as effective at pain relief as the prescription drug celecoxib, but with an excellent safety profile, Flexiseq has been hailed in Europe as a Wondergel*. Flexiseq has already won The Innovation Award 2013 from the Federal Association of German Pharmacists for its break through Nano Technology.
Berlin 25.1013 "Get people moving – experience success". This slogan of the German Congress of Orthopaedics and Trauma Surgery also held true for the symposium organised by Pro Bono Bio, which reported on a new, innovative and award-winning therapy option for osteoarthritis patients. Studies were presented proving the efficacy of the topical gel for pain and joint stiffness associated with osteoarthritis as well as personal experiences of the presenters with FLEXISEQ™ based on patient cases. FLEXISEQ contains no pharmacologically active substances, but works through the use of Sequessome™ vesicles, tiny phospholipid droplets that penetrate the skin into the joint and lubricate the damaged cartilage. Worldwide marketing of the gel, developed and produced in Germany, is pending after initial successes in Europe and Asia, as company head John Mayo reported.
555 patient clinical trial provides further evidence that FLEXISEQ is effective in reducing pain for osteoarthritis patients with a particularly strong safety profile.
London, England 6 September 2013 –Key clinical trial data supporting Pro Bono Bio’s (“PBB”) drug-free osteoarthritis treatment FLEXISEQ, have been published in The Journal of Rheumatology. This is the latest high profile publication after winning the German Pharmacy Industry award for innovation in January 2013.
The publication reports that FLEXISEQ (TDT 064) was very effective in managing the pain associated with osteoarthritis (OA) and was again found to have a much stronger safety profile than other treatments.
KUALA LUMPUR: FARMASIA Sdn Bhd and Pro Bono Bio recently handed over pain relief gel Flexiseq to Lembaga Tabung Haji for pilgrims performing their haj this year.
The donation is a continuation of Farmasia's CSR activities after the company's first donation of Flexiseq to Malaysian pilgrims in November last year.
For Pro Bono Bio, this donation is part of the company's humanitarian mission and follows its donation of Flexiseq to the haj pilgrims of Senegal last year.
"We have decided to continue this initiative due to the positive response we received from last year's pilgrims who used the gel.
"According to the pilgrims, applying the gel significantly eased the pain caused by osteoarthritis in their knees and that helped them tremendously with their journey,"said Farmasia Sdn Bhd director Zohrah Al-Aidruss.
Kuala Lumpur & London August 1, 2013 - FARMASIA Sdn Bhd and Pro Bono Bio donated FLEXISEQ™ Gel to Lembaga Tabung Haji for pilgrims performing their Hajj this year. The donation was acknowledged during a ceremony held at the Lembaga Tabung Haji Headquarters in Kuala Lumpur today. The event was attended by YBhg Dato’ Seri Jamil Khir Bin Baharom, Minister in the Prime Minister’s Department, the Chairman of Lembaga Tabung Haji, YBhg Datuk Haji Abdul Azeez Bin Abdul Rahim, and it’s Chief Executive Officer, YBhg Dato’ Paduka Ismee Ismail.
FLEXISEQ has also been purchased by Tabung Haji and will form part of the medical team’s treatment regime for pilgrims suffering from OA during their Hajj. This purchase, which comes very soon after the product’s introduction into Malaysia, is a sign of the overall confidence in the product’s benefit.
Besides Tabung Haji, several other institutions and foundations have purchased FLEXISEQ for their pilgrims, with several more showing keen interest in its benefits. This will ensure that a total of over 7,000 Malaysian pilgrims will benefit from FLEXISEQ during the Hajj this year.
For millions of sufferers of chronic pain, the dependence on painkillers for relief brings with it a risk. High doses of painkillers have been found to increase the risk of heart attacks, strokes and heart failure, and complications such as bleeding ulcers when taken in high quantities, according to the largest study of its kind, by Oxford University, which was recently published in the renowned medical journal The Lancet. The drugs, which are known as non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used by people with arthritis and other forms of chronic pain.
The study analysed the results of 754 clinical trials of NSAIDs, including diclofenac, ibuprofen, naproxen and the COX-II inhibitors : celecoxib, rofecoxib and lumiracoxib. It confirmed that these drugs significantly increased the risks of cardiovascular side effects, including death, and gastrointestinal problems, including internal bleeding.
Florence Yong used to enjoy her brisk morning walks. But her inability to move around freely has now confined her to her home. For Yong and many others, the onset of age comes with joint pains. While free from other conditions due to her healthy lifestyle and diet, the onset of joint pain is something that has affected her in more ways than one.
Osteoarthritis (OA) may sound like a rare health problem, but it affects about 10% to 20% of the Malaysian adult population. If not treated adequately or properly managed, the pain can interfere with daily activities, seriously impeding our mobility and flexibility of movement. The most common cause is the thinning of the joint cartilage due to natural wear and tear as one ages. Regardless of the root cause, OA leads to pain. Joints such as the knees, fingers or elbows become inflamed and stiff after a certain period of inactivity, making it painful and difficult to move.
Berlin, London, Dublin, Kuala Lumpur, Singapore, Valletta 20 June 2013
The renowned medical journal The Lancet has recently published a study by Oxford University, which confirms the potential dangers in a class of drugs commonly prescribed in patients with chronic diseases such as osteoarthritis. The study analysed the results of 754 clinical trials of Non Steroidal Anti Inflammatory (NSAID) Drugs, including diclofenac, ibuprofen, naproxen and the COX-II inhibitors: celecoxib, rofecoxib, etoricoxib and lumiracoxib. It confirmed that these drugs significantly increased risks of cardiovascular side effects, including death, and gastrointestinal problems including internal bleeding.
This is yet further confirmation of the potentially fatal risks of this commonly prescribed class of painkillers: In 2009 a Danish national cohort study involving millions of people showed that taking ibuprofen, diclofenac, naproxen, rofecoxib and celecoxib significantly raised the risk of death and heart attack, even after a short treatment period.
All rights reserved.